In chronic insomniac patients, DSIP improved sleep in a double-blind study, supporting a sleep-normalizing (delta-wave) effect.
DSIP (Delta Sleep-Inducing Peptide)
Delta sleep-inducing peptide for improved sleep quality

Overview
Last reviewed: 2026-08-18
Identity & Aliases
Also known as
Status: Research compound - Neuropeptide
Full composition (formula, molecular weight, sequence) in Quick Facts →
Research Areas
Available Evidence
A double-blind study in chronic insomniacs (Neuropsychobiology 1992) reported improved sleep with DSIP, and an earlier Lancet report (1981) described improved sleep in insomniacs. Small studies also reported reduced pain episodes in chronic pain patients (Eur Neurol 1984) and use as an adjunct in opioid detoxification; this clinical literature is old, small, and never replicated in modern trials.
Rodent studies show DSIP increases delta-wave sleep and modulates stress-related endocrine responses (e.g., corticosterone), supporting a neuroendocrine role beyond sleep.
DSIP shows no classic sedative pharmacology; laboratory work has focused on rapid enzymatic degradation in plasma (very short half-life) and receptor-binding/neuroendocrine assays.
The peptide is rapidly degraded and its half-life is short, and reproducible sleep-promoting efficacy in modern controlled trials has not been established; most clinical evidence dates from the 1980s–1990s and is methodologically limited.
Key Studies & Findings
Synthetic DSIP improved sleep in insomniacs in an early controlled report.
A clinical pilot study reported therapeutic effects of DSIP in patients with chronic, pronounced pain episodes.
Benefits & Effects
Induces physiological sleep
Reduces stress
Normalizes blood pressure
Improves hormone levels.
Four consecutive injections completely normalized disturbed sleep in insomniacs
Improved alertness during wakefulness
Better stress tolerance and coping
Motor function recovery after stroke
Induces physiological sleep
Reduces stress
Normalizes blood pressure
Improves hormone levels.
Side Effects & Safety
Interaction
Avoid: Stimulants
Interaction
Avoid: Stimulants
Good tolerability; bell-shaped dose-response curves noted
Severe side effect
Onset: Immediate
Management: ONLY during reperfusion, NOT during ischemia
Limitations & Open Questions
Pharmacology
Reported Research Dosing
Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.
100-300mcg before bed
Research Protocols
Sleep Enhancement
- Dose
- 100-200mcg
- Frequency
- Once nightly
- Route
- Subcutaneous
Chronic Pain
- Dose
- 250-300mcg
- Frequency
- Daily
- Route
- IV or SubQ
Stress Management
- Dose
- 150mcg
- Frequency
- Evening
- Route
- Subcutaneous
Withdrawal Support
- Dose
- 200-300mcg
- Frequency
- Twice daily
- Route
- IV preferred
Athletic Recovery
- Dose
- 100-150mcg
- Frequency
- Post-training
- Route
- Subcutaneous
Research protocols are for educational purposes only. Always consult qualified medical professionals.
Frequently Asked Questions
Is DSIP approved as a sleep medication?
No. DSIP is not an approved drug; it is sold as a research peptide, and the supporting clinical studies are old and small.
Does DSIP work like a sleeping pill?
No — it is not a sedative. Research suggests it modulates sleep architecture (delta/deep sleep) and stress hormones, but modern confirmatory trials are lacking.
Research Citations
Kovalzon VM, Strekalova TV (2006)
Yehuda S, Carasso RL (1988)
Graf MV, Kastin AJ (1986)
Mu X, Qu L, Yin L, Wang L, Liu X, Liu D (2024)
+ 38 more citations
Related Resources
Quick Facts
Formula
C35H48N10O15
Molecular Weight
848.82
Sequence
WAGGDASGE
Mechanism
Sleep quality enhancement and stress management peptide
Safety Information
Research compound only. Limited human safety data available.
Citations
43Kovalzon VM, Strekalova TV (2006)
Yehuda S, Carasso RL (1988)
Graf MV, Kastin AJ (1986)
Mu X, Qu L, Yin L, Wang L, Liu X, Liu D (2024)
+ 38 more citations